Global Macrogol Laxative Market Size (2023 - 2030)

In 2022, the Global Macrogol Laxative Market was valued at $2.03 billion, and is projected to reach a market size of $2.61 billion by 2030. Over the forecast period of 2023-2030, market is projected to grow at a CAGR of 3.2%.

Market Overview: 

Constipation is a very regular condition globally and affects the physical as well as the emotional well-being of both adults and children. It is an upsetting condition that affects almost 12% of the global population and can be caused due to many factors such as low fiber in the diet, lack of exercise, pregnancy, and others. Moreover, if it persists for several months, it can become chronic and persistent. The rate of occurrence of constipation varies from 2.5% to 79% in adults and in children, it is almost 0.7% to 29.6%. It is more prevalent in people having the age 60 years and above and becomes frequent with the increasing age. Additionally, people from lower income groups have significantly more frequent cases than the wealthier ones. Its frequency usually decreases in people with years of parental education and people with high body mass index and sedentary lifestyles or less physical activity. Further, other risk factors are low-fiber food intake, living in a densely populated community, constipation in the family history, and suffering from anxiety, stress, and depression. Macrogol Laxative is a safe, effective, and efficient treatment for constipation for both children and elderly patients and can work in several ways, including emollient, contact, bulk-forming, and osmotic machines. Owing to it containing a higher amount of water content, the volume of the fecal mass increases which further stimulates bowel movements forcefully with swelling of the walls of the colon. The rise in water content softens the stool for easy motion. A comparative lower dose of Macrogol aids in improving stool frequency in patients with chronic constipation conditions. It has been proven to be effective in the long term without an increase in the dosage over time. Although it is not proven to have severe side effects, it may cause diarrhea and bloat in some patients.  

COVID-19 Impact on Macrogol Laxative Market: 

The COVID-19 outbreak began in Wuhan (China) in December 2019, and since then, it has stretched out around the globe at a very rapid pace. China, Italy, Iran, Spain, the Republic of Korea, France, Germany, and the US are among the worst-hit countries in terms of the number of positive cases and reported deaths. The COVID-19 outbreak has severely affected economies and industries in various countries due to lockdowns and business shutdowns. The global healthcare and pharmacy industry are the major industries that faced serious disruptions such as supply chain breaks, technology events, and office shutdowns as a result of this outbreak. It hampered the overall growth in three main ways: by affecting production and demand, its financial impact on the manufacturing industry, by supply-chain disruptions. Also, due to shutdowns and the restrictive lifestyle that followed the lockdown, the colon’s circadian rhythm got disrupted by reduced physical activity, poor sleeping patterns, unhealthy eating habits, and stress. This increased the demand for constipation laxatives but major disruptions and destruction in the delivery mechanism of healthcare products across the world restrained its growth during the pandemic. The U.S. is the global manufacturing center, with the presence of the largest raw material suppliers for Macrogol Laxative. The overall market shutdown due to COVID-19 is also affecting the growth due to the shutting down of factories, disruptions in the supply chain, and a downturn in the world economy. 

Market Drivers: 

Growing demand for R&D and new technology in the Pharmaceutical Industry is boosting the market growth: 

Private capital investment and spending on pharmaceutical R&D and the approval and launch of new drugs have both increased remarkably in recent years, renewing a decades-long trend that was disrupted in 2008 as generic versions of some high-selling drugs became available and as the 2007–2009 recession occurred. Particularly, spending on drug R&D elevated by nearly 65% between 2017 and 2020. Many of the drugs approved recently are high-priced drugs for relatively small numbers of potential patients. Therefore, increased competition and constant innovations in the pharmacy industry are escalating the global Macrogol Laxatives market. 

The increasing occurrence of eating disorders among people is boosting demand for Macrogol Laxative:  

Irregular bowel has become very prevalent as a result of irregular eating patterns, sedentary lifestyles, and other stress-related habits. An increase in gastric diseases due to unhealthy eating habits will fuel the market’s growth rate. Further, government initiatives to spread awareness about health will enhance the demand for laxatives growing the market size.  

Surging investments in the healthcare industry are fostering the market:  

The rising investments in the healthcare industry are helping in improving its infrastructure along with government organizations implementing several strategies and initiatives to improve the status of healthcare worldwide. 

The growing geriatric population is boosting the demand for Macrogol Laxatives in the market: 

The surging geriatric population is estimated to boost the market's growth rate. Bowel movement disorders are becoming increasingly common as people age. This is because of their body’s inability to digest meals. Muscle loss and inefficient function may lead to major problems. As a result, senior citizens are rapidly using macrogol laxatives driving the market. 

Market Restraints: 

Patent expiration resulting in hindrance to the market growth: 

Driven by an aging population and an increasing number of patent expirations, the global Macrogol Laxatives market is facing declining profit margins. The key patents of multi-billion-dollar brand drugs are set to expire within the next few years. The loss of over 300,000 pharmaceutical jobs over the past few years has been mainly driven by the predicted loss of revenue from drugs that will lose patent protection by 2025. Along the trends of the past several years, the next five years are likely to reflect a huge imbalance between new product introductions and patent losses. This is the major factor limiting global Macrogol Laxatives market growth 

MACROGOL LAXATIVE MARKET REPORT COVERAGE:

This research report on the Macrogol Laxatives Market has been segmented and sub-segmented based on Drug Name, Diseases, Age Group, Administration Route, Distribution Channel, Region, and Key Companies.  

Macrogol Laxatives Market – By Drug Name. 

• Movicol 
• Casenlax 
• VistaPrep 
• CosmoCol 
• Molaxole 
• Endofalk 
• Glycoprep 
• Forlax 
• Laxido 
• MiraLAX 
• Other Macrogols 

Based on the drug name, the Macrogol Laxatives Market has been segmented into ten major drugs – Movicol, Casenlax, VistaPrep, CosmoCol, Molaxole, Endofalk, Glycoprep, Forlax, Laxido, and MiraLAX. 

Macrogol Laxatives Market – By Diseases. 

• Inflammatory Bowel Diseases (IBD) 
• Irritable Bowel Syndrome (IBS) 
• Drug Induced Constipation (DIC) 
• Other

Based on the diseases for which it may be used, the Macrogol Laxatives Market has been segmented into three major categories – Inflammatory Bowel Diseases (IBD), irritable bowel syndrome (IBS), and Drug-Induced Constipation (DIC). 

The Inflammatory Bowel Diseases segment dominates the Macrogol Laxatives market. Laxatives may also be prescribed for people with irritable bowel syndrome.  

Macrogol Laxatives Market – By Age Group. 

• Baby Boomers and Older 
• Generation X 
• Millennials 
• Generation Z 
• Generation Alpha 

Based on the age group, the Macrogol Laxatives Market has been segmented into five categories – Baby Boomers and Older, Generation X, Millennials, Generation Z, and Generation Alpha. 

Adults segment dominates the global Macrogol Laxatives market. The growing number of patients experiencing stool disorders due to bad food habits results in the growth of the macrogol laxatives market.  

Macrogol Laxatives Market - By Administration Route  

• Oral 
• Nasogastric 
• Ophthalmic 
• Topical 

Based on the administration route, the Macrogol Laxatives Market has been segmented into four categories – Oral, Nasogastric, Ophthalmic, and Topical. 

The oral drugs segment dominates the Macrogol Laxatives Market. Oral laxatives are taken by mouth for smooth bowel movements to ease constipation. Rectal laxatives are generally used for children.  

Macrogol Laxatives Market – By Distribution Channel. 

• Direct Sales 
• Whole Sales 
• Others 

Based on the distribution channel, the Macrogol Laxatives Market has been segmented into three categories – Direct Sales, Whole Sales, and Others. 

The direct sales segment dominates the market in terms of revenue. As these laxatives can be found over the counter, they can easily be available to any individual experiencing an upset stomach, growing the macrogol laxative market. 

Macrogol Laxatives Market – By Region. 

• North America 
• Europe 
• Asia-Pacific 
• South America 
• Middle-East and Africa 

Based on the region, the Macrogol Laxatives Market has been segmented into five major regions – North America, Europe, Asia-Pacific, South America, Middle-East, and Africa. 

The North American region holds 38% of the global Macrogol Laxatives market in terms of revenue share. The rapid increase in awareness of gastric diseases within the population is an important reason for the dominance of this region. 

Macrogol Laxatives Market – By Companies. 

1. Abbott Laboratories  
2. AstraZeneca, Bayer 
3. Boehringer Ingelheim 
4. Braintree Laboratories  
5. GlaxoSmithKline  
6. Procter & Gamble Company  
7. Purdue Pharma 
8. Sucampo Pharmaceuticals 
9. Takeda Pharmaceutical Company 

Recent Industry Developments: 

• In March 2021, Purdue Pharma L.P. announced the launch of two Products namely Senokot Laxative Gummies – Blueberry Pomegranate and Senokot Tea used as the treatment for constipation.